Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 145.34 million. The enterprise value is 128.18 million.
Market Cap | 145.34M |
Enterprise Value | 128.18M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
Earnings Date | Apr 25, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 23.04% in one year.
Current Share Class | n/a |
Shares Outstanding | 47.40M |
Shares Change (YoY) | +23.04% |
Shares Change (QoQ) | +21.39% |
Owned by Insiders (%) | 2.70% |
Owned by Institutions (%) | 20.49% |
Float | 25.53M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.12 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -3.83 |
EV / Sales | 3.04 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -83.72 |
Financial Position
The company has a current ratio of 1.42
Current Ratio | 1.42 |
Quick Ratio | 1.36 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -32.11 |
Interest Coverage | -2.79 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -22.02% |
Return on Capital (ROIC) | -101.38% |
Revenue Per Employee | 383,673 |
Profits Per Employee | -304,300 |
Employee Count | 102 |
Asset Turnover | 0.66 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.30% in the last 52 weeks. The beta is 1.29, so Nanobiotix's price volatility has been higher than the market average.
Beta (5Y) | 1.29 |
52-Week Price Change | -48.30% |
50-Day Moving Average | 3.59 |
200-Day Moving Average | 4.71 |
Relative Strength Index (RSI) | 41.01 |
Average Volume (20 Days) | 145,275 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 42.20 million and -33.47 million in losses. Loss per share was -0.78.
Revenue | 42.20M |
Gross Profit | 42.20M |
Operating Income | -22.39M |
Pretax Income | -33.21M |
Net Income | -33.47M |
EBITDA | -22.30M |
EBIT | -22.39M |
Loss Per Share | -0.78 |
Balance Sheet
The company has 66.34 million in cash and 49.17 million in debt, giving a net cash position of 17.17 million or 0.36 per share.
Cash & Cash Equivalents | 66.34M |
Total Debt | 49.17M |
Net Cash | 17.17M |
Net Cash Per Share | 0.36 |
Equity (Book Value) | -21.78M |
Book Value Per Share | -0.46 |
Working Capital | 23.94M |
Cash Flow
In the last 12 months, operating cash flow was -1.04 million and capital expenditures -494,000, giving a free cash flow of -1.53 million.
Operating Cash Flow | -1.04M |
Capital Expenditures | -494,000 |
Free Cash Flow | -1.53M |
FCF Per Share | -0.03 |
Margins
Gross margin is 100.00%, with operating and profit margins of -53.06% and -79.31%.
Gross Margin | 100.00% |
Operating Margin | -53.06% |
Pretax Margin | -78.69% |
Profit Margin | -79.31% |
EBITDA Margin | -52.83% |
EBIT Margin | -53.06% |
FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -23.04% |
Shareholder Yield | -23.04% |
Earnings Yield | -25.45% |
FCF Yield | -1.05% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.97. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -3.97 |
Piotroski F-Score | n/a |